BMY Technical Analysis

As of date:	12/4/2023
BMY stock price:	49.98
BMY 50 DMA:	53.49
BMY 200 DMA:	61.47
BMY MACD (200-50):	7.98
BMY RSI:	48.98

Extremely Overbought
	48.98
Extremely Oversold

Also see:
BMY Market Cap History
BMY Shares Outstanding History
BMY YTD Return

Quotes delayed 20 minutes

Free BMY Email Alerts:
Get Dividend Alerts

Get SEC Filing Alerts

Viking Therapeutics Breaks Above 200-Day Moving Average - Bullish for VKTX
48 minutes ago

EBTC Makes Bullish Cross Above Critical Moving Average
48 minutes ago

PLBC Crosses Above Key Moving Average Level
48 minutes ago

RARE Crosses Above Key Moving Average Level
48 minutes ago

Bullish Two Hundred Day Moving Average Cross - SAVA
1 hour, 15 minutes ago

Bullish Two Hundred Day Moving Average Cross - CIVB
1 hour, 17 minutes ago

SASR Crosses Above Key Moving Average Level
1 hour, 18 minutes ago

Bullish Two Hundred Day Moving Average Cross - CMCO
1 hour, 20 minutes ago

Gilead Sciences Breaks Above 200-Day Moving Average - Bullish for GILD
1 hour, 21 minutes ago

CBSH Crosses Above Key Moving Average Level
1 hour, 21 minutes ago

TMP Makes Bullish Cross Above Critical Moving Average
1 hour, 27 minutes ago

Bullish Two Hundred Day Moving Average Cross - PDI
1 hour, 36 minutes ago

Bullish Two Hundred Day Moving Average Cross - RC
1 hour, 36 minutes ago

Bullish Two Hundred Day Moving Average Cross - PDM
1 hour, 36 minutes ago

TRNO Makes Bullish Cross Above Critical Moving Average
1 hour, 41 minutes ago

More Technical Analysis News

Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor T-cell therapies. Co.'s primary product includes Eliquis® - Eliquis (apixaban), which is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.

When researching a stock like Bristol-Myers Squibb, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from BMY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for BMY stock — the real life supply and demand for the stock over time — and examines that data in different ways.

10 Most Oversold S&P 500 Stocks

10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying

10 ETFs With Most Upside To Targets

The DividendRank Top 25

Warren Buffett Dividend Stocks

10 Cheap Dividend Stocks Under $10

10 Top DividendRank'ed Energy Stocks

The 10 Highest Yielding Preferred Stocks

The 15 Most Active S&P Call & Put Options

Video: Technical Analysis

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Bristol-Myers Squibb (BMY) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

BSX Technical Analysis
CAH Technical Analysis
CI Technical Analysis
CNC Technical Analysis
COO Technical Analysis
COR Technical Analysis
CRL Technical Analysis
CTLT Technical Analysis
CVS Technical Analysis
DGX Technical Analysis
More Healthcare companies »

Join TechnicalAnalysisChannel.com
Create a FREE account to continue
Already have an account? LOG IN

Full Disclaimer & Terms of Use and Privacy Policy. Important: If you are in Canada or the European Union, you must click here for alternate registration page.

✓

Immediate access to our BMY Technical Analysis page as well as our full coverage universe of stocks

✓

Complimentary report on monthly dividend paying stocks

✓

Daily market updates from our Contrarian Outlook team

✓

Join FREE with just your email address

Welcome back!

TechnicalAnalysisChannel.com and parent company BNK Invest, Inc. value our relationship with you and would like to continue providing accurate and tailored communications to fit your investing needs. To receive our publications and other relevant communications, Canada's anti-spam legislation (''CASL'') and the European Union's General Data Protection Regulation (''GPDR'') requires us to obtain your express consent. Please provide your consent to continue. In any email we send, you will be given the option to withdraw your consent or unsubscribe from any or all of our newsletters or publications at any time.

BMY Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2023, All Rights Reserved